Neurophysiological Attention Test (NAT) for Objective Assessment of Adult ADHD

Completed

Conditions studied: Attention Deficit Hyperactivity Disorder

In brief

The purpose of this study is to refine a new assessment tool for Attention Deficit/Hyperactivity Disorder (ADHD) and then to test its validity (i.e. ability to discriminate between individuals with ADHD and healthy controls.

Key facts

Study ID

NCT02756286

Run by

Think Now Incorporated

People needed

258

Starts

2017-01-01

Expected to finish

2018-07-05

Last updated by the study team

2018-09-19

Who can join

Age: 18 and older, up to 40. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Specific inclusion criteria for ADHD are:
• meet established Diagnositic and Statistical Manual-5 criteria for ADHD predominately inattentive or combined subtype with clinically significant levels of impairment, diagnosed by structured clinical interview, the Mini International Neuropsychiatric Interview, and corroborating information
• Clinical Global Impression-Severity (CGI-S) score ≥ 4 for ADHD
• no lifetime history of DSM-5 bipolar disorder, psychotic disorder, pervasive developmental disorder, obsessive-compulsive disorder, substance abuse, or substance dependence (except nicotine) as assessed with the Mini International Neuropsychiatric Interview (MINI).
• able in the opinion of the investigator to complete all required study procedures.

You may not qualify if…

• Exclusion criteria for both groups are:
• History of diagnosis of childhood disorder other than ADHD (e.g. autism, dyslexia)
• history of any general medical condition likely to require chronic use of medication with identified central nervous system (CNS) effects suspected to alter cognitive performance
• history of seizure disorder, brain tumor, other major neurological disorder or head injury resulting in loss of consciousness
• serious oxygen deprivation
• current psychopathology requiring ongoing treatment with antipsychotic medications, mood stabilizers, benzodiazepines, or anticonvulsants
• current untreated psychopathology which is rated to be primary in terms of severity (greater than ADHD severity)
• current treatment with guanfacine.

Where it is running

• University of California Berkeley — Berkeley, California, United States
• UCLA Semel Institute — Los Angeles, California, United States
• Oregon Health & Science University — Portland, Oregon, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.